Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1732 - Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer


09 Sep 2017


Poster display session


Surgical Oncology;  Radiation Oncology;  Ovarian Cancer


Mingyi Zhou


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


M. Zhou, X. Wang, L. Li, C. Wang, D. Wang

Author affiliations

  • Department Of Gynecology, Liaoning Cancer Hospital & Institute, 110042 - Shenyang/CN


Abstract 1732


We evaluated the ability of our newly developed laparotomy-based model to predict optimal primary debulking surgery (PDS) and long-term outcomes of stage IIIC epithelial ovarian cancer (EOC).


Data of 400 IIIC EOC patients who underwent laparotomy were retrospectively analyzed to investigate predictors of optimal PDS. Parameters including infiltration of the bowel, peritoneum, diaphragm, hepatic surface, spleen, and stomach; omental caking; mesenteric retraction; and metastasis of the pelvic and para-aortic lymph nodes increased the difficulty of surgery. The parameters with a specificity ≥75%, positive predictive value ≥50%, and negative predictive value ≥50% were included in the final predictive index value (PIV) model. Each parameter was assigned a score based on the strength of its statistical association, and a total PIV was tabulated for each patient. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive ability of the model. Subgroup analyses were performed in patients with RD > 1 cm and ≤1 cm.


After PDS, 223 (55.8%) patients with RD ≤ 1 cm had longer progression-free survival (PFS) and overall survival (OS) than patients with RD > 1 cm (PFS: 24.3 vs. 15.9 months; P 


When PDS left RD of ≤ 1 cm, patients with a PIV of  1 cm, patients who were sensitive to platinum had a better prognosis. Additionally, patients with a lymph node rate of > 32.5% were more likely to progress.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.